10 Participants Needed

VX-880 for Type 1 Diabetes

Recruiting at 4 trial locations
MI
Overseen ByMedical Information
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Vertex Pharmaceuticals Incorporated
Must be taking: Immunosuppressants
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

Eligibility Criteria

This trial is for people with Type 1 Diabetes who have had a kidney transplant. Participants must have been insulin-dependent for at least 5 years, be on a stable immunosuppression regimen for at least 4 weeks, and consistently use a continuous glucose monitor (CGM) for the same duration.

Inclusion Criteria

I have been dependent on insulin for 5 years or more due to Type 1 Diabetes.
I've been on a steady dose of specific immunosuppressants for over 4 weeks.
I have been using a CGM for at least 4 weeks and am willing to continue using it.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive VX-880 to evaluate efficacy, safety, and tolerability

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 weeks

Treatment Details

Interventions

  • VX-880
Trial Overview The study tests VX-880's effectiveness, safety, and tolerability in individuals with Type 1 Diabetes who also had a kidney transplant. It aims to see how well VX-880 works as a biological/vaccine intervention in this specific patient group.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: VX-880Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vertex Pharmaceuticals Incorporated

Lead Sponsor

Trials
267
Recruited
36,100+
Dr. David Altshuler profile image

Dr. David Altshuler

Vertex Pharmaceuticals Incorporated

Chief Medical Officer since 2020

MD, PhD

Dr. Reshma Kewalramani profile image

Dr. Reshma Kewalramani

Vertex Pharmaceuticals Incorporated

Chief Executive Officer since 2020

MD, trained in internal medicine and nephrology

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security